Compare ELVA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVA | AVIR |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.5M | 318.0M |
| IPO Year | 2021 | 2020 |
| Metric | ELVA | AVIR |
|---|---|---|
| Price | $7.98 | $6.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $14.00 | $8.00 |
| AVG Volume (30 Days) | 431.4K | ★ 569.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $56.86 | N/A |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $2.46 |
| 52 Week High | $11.88 | $6.45 |
| Indicator | ELVA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 77.84 |
| Support Level | $7.11 | $3.33 |
| Resistance Level | $9.12 | N/A |
| Average True Range (ATR) | 0.55 | 0.30 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 49.44 | 80.68 |
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).